Vericel Co. (NASDAQ:VCEL) Given Consensus Recommendation of “Buy” by Analysts

Vericel Co. (NASDAQ:VCEL) has earned an average rating of “Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $60.86.

A number of equities analysts have weighed in on the stock. Truist Financial dropped their price target on shares of Vericel from $61.00 to $51.00 and set a “buy” rating for the company in a research report on Friday, April 11th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Finally, Canaccord Genuity Group boosted their price target on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd.

Vericel Trading Up 1.0 %

Shares of NASDAQ:VCEL opened at $41.23 on Friday. Vericel has a 12-month low of $37.76 and a 12-month high of $63.00. The company has a market cap of $2.07 billion, a PE ratio of 687.28 and a beta of 1.61. The stock has a 50 day moving average of $47.75 and a 200 day moving average of $51.31.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 24,850 shares of Vericel stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total value of $1,040,966.50. Following the completion of the transaction, the chief executive officer now directly owns 260,354 shares of the company’s stock, valued at $10,906,229.06. This trade represents a 8.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert L. Md Zerbe sold 2,500 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now owns 26,595 shares in the company, valued at $1,662,187.50. This represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 58,942 shares of company stock worth $2,724,548 in the last quarter. 7.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vericel

Several institutional investors have recently modified their holdings of the stock. Handelsbanken Fonder AB raised its holdings in Vericel by 24.3% during the 1st quarter. Handelsbanken Fonder AB now owns 20,479 shares of the biotechnology company’s stock valued at $914,000 after buying an additional 4,000 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Vericel by 29.3% in the 1st quarter. SG Americas Securities LLC now owns 12,546 shares of the biotechnology company’s stock worth $560,000 after acquiring an additional 2,840 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Vericel by 34.8% during the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 748 shares during the period. Portside Wealth Group LLC grew its holdings in Vericel by 9.9% during the 1st quarter. Portside Wealth Group LLC now owns 6,546 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 591 shares during the last quarter. Finally, Congress Asset Management Co. raised its position in Vericel by 1.6% in the 1st quarter. Congress Asset Management Co. now owns 1,476,718 shares of the biotechnology company’s stock worth $65,891,000 after purchasing an additional 22,579 shares during the period.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.